MX2018007230A - Terapia genica para trastornos oculares. - Google Patents
Terapia genica para trastornos oculares.Info
- Publication number
- MX2018007230A MX2018007230A MX2018007230A MX2018007230A MX2018007230A MX 2018007230 A MX2018007230 A MX 2018007230A MX 2018007230 A MX2018007230 A MX 2018007230A MX 2018007230 A MX2018007230 A MX 2018007230A MX 2018007230 A MX2018007230 A MX 2018007230A
- Authority
- MX
- Mexico
- Prior art keywords
- ocular disorders
- adeno
- nucleic acid
- acid molecule
- sequence encoding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/04—Uses of viruses as vector in vivo
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan composiciones y métodos para tratar trastornos oculares en un sujeto; en un aspecto se proporciona un vector viral adenoasociado que incluye una molécula de ácido nucleico que comprende una secuencia que codifica CNGA3; en otro aspecto se proporciona un vector viral adenoasociado que incluye una molécula de ácido nucleico que comprende una secuencia que codifica CNGB3; en otro aspecto se proporciona un vector viral adenoasociado que incluye una molécula de ácido nucleico que comprende una secuencia que codifica REP-1; en modalidades deseadas, el sujeto es un ser humano, un gato, un perro, una oveja o un primate no humano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562266789P | 2015-12-14 | 2015-12-14 | |
PCT/US2016/066402 WO2017106202A2 (en) | 2015-12-14 | 2016-12-13 | Gene therapy for ocular disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018007230A true MX2018007230A (es) | 2018-11-09 |
Family
ID=58455636
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018007230A MX2018007230A (es) | 2015-12-14 | 2016-12-13 | Terapia genica para trastornos oculares. |
MX2022010959A MX2022010959A (es) | 2015-12-14 | 2018-06-13 | Terapia genica para trastornos oculares. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022010959A MX2022010959A (es) | 2015-12-14 | 2018-06-13 | Terapia genica para trastornos oculares. |
Country Status (13)
Country | Link |
---|---|
US (2) | US11090392B2 (es) |
EP (2) | EP3795180A1 (es) |
JP (2) | JP7057281B2 (es) |
KR (1) | KR20180099719A (es) |
CN (1) | CN109069668B (es) |
AU (1) | AU2016370487C1 (es) |
BR (1) | BR112018011838A2 (es) |
CA (1) | CA3008264A1 (es) |
ES (1) | ES2826384T3 (es) |
HK (1) | HK1258518A1 (es) |
MX (2) | MX2018007230A (es) |
RU (1) | RU2762747C2 (es) |
WO (1) | WO2017106202A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017106202A2 (en) * | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
PL3377637T3 (pl) * | 2016-04-08 | 2020-09-07 | Krystal Biotech, Inc. | Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry |
EP3490613A4 (en) * | 2016-07-26 | 2020-03-04 | Cornell University | GENE THERAPY FOR THE TREATMENT OF ALDEHYDE DEHYDROGENASE DEFICIT |
EP3638316A4 (en) * | 2017-06-14 | 2021-03-24 | The Trustees Of The University Of Pennsylvania | GENE THERAPY FOR EYE DISORDERS |
CN110889859A (zh) * | 2019-11-11 | 2020-03-17 | 珠海上工医信科技有限公司 | 一种用于眼底图像血管分割的u型网络 |
US20240091380A1 (en) | 2021-02-01 | 2024-03-21 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
BR112023016997A2 (pt) * | 2021-02-26 | 2023-11-07 | Logicbio Therapeutics Inc | Fabricação e uso de vetores aav recombinantes |
BR112023020209A2 (pt) | 2021-04-02 | 2023-12-19 | Krystal Biotech Inc | Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer |
WO2023014892A1 (en) * | 2021-08-04 | 2023-02-09 | Alpine Biotherapeutics Corporation | Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
AU728220B2 (en) | 1997-04-14 | 2001-01-04 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
CA2348382C (en) | 1998-11-10 | 2013-09-17 | The University Of North Carolina At Chapel Hill | Chimeric parvovirus vectors and methods of making and administering the same |
AU781958C (en) | 1999-08-09 | 2006-03-30 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
DE60139471D1 (de) | 2000-06-01 | 2009-09-17 | Univ North Carolina | Verfahren und zusammensetzungen zur kontrollierter abgabe von rekombinant parvovirus vektoren |
JP2005500008A (ja) | 2001-01-19 | 2005-01-06 | インサイト・ゲノミックス・インコーポレイテッド | 受容体および膜結合タンパク質 |
EP1381276A4 (en) | 2001-04-13 | 2005-02-02 | Univ Pennsylvania | METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION |
NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
ES2648241T3 (es) | 2003-09-30 | 2017-12-29 | The Trustees Of The University Of Pennsylvania | Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos |
ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
WO2007120542A2 (en) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid library and aav capsid proteins |
WO2010005533A2 (en) | 2008-06-30 | 2010-01-14 | The Johns Hopkins University | Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa |
US20110305772A1 (en) | 2009-02-26 | 2011-12-15 | The Johns Hopkins University | Compositions and methods for ex vivo hepatic nucleic acid delivery |
RU2444977C2 (ru) | 2009-08-03 | 2012-03-20 | Федеральное государственное учреждение "МОСКОВСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ ИМЕНИ ГЕЛЬМГОЛЬЦА ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ВЫСОКОТЕХНОЛОГИЧНОЙ МЕДИЦИНСКОЙ ПОМОЩИ" | Способ диагностики ахроматопсии |
WO2011034947A2 (en) * | 2009-09-15 | 2011-03-24 | University Of Washington | Reagents and methods for modulating cone photoreceptor activity |
CA2793633A1 (en) | 2010-03-29 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
EP3591055A1 (en) | 2011-01-07 | 2020-01-08 | Applied Genetic Technologies Corporation | Promoters derived from the 5' nontranslated region (5'-ntr) of the human cyclic nucleotide gated beta 3 (cngb3) gene, expression cassettes and vectors comprising said promoters, for use treating achromatopsia and other diseases |
GB201103062D0 (en) * | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
US9249425B2 (en) | 2011-05-16 | 2016-02-02 | The Trustees Of The University Of Pennslyvania | Proviral plasmids and production of recombinant adeno-associated virus |
FR2977562B1 (fr) | 2011-07-06 | 2016-12-23 | Gaztransport Et Technigaz | Cuve etanche et thermiquement isolante integree dans une structure porteuse |
WO2013063601A1 (en) * | 2011-10-28 | 2013-05-02 | University Of Florida Research Foundation, Inc. | Chimeric promoter for cone photoreceptor targeted gene therapy |
WO2013086515A1 (en) | 2011-12-09 | 2013-06-13 | The Johns Hopkins University | Compositions and methods for the prevention or treatment of diabetic complications |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
WO2014011210A1 (en) | 2012-07-11 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
WO2014024282A1 (ja) | 2012-08-08 | 2014-02-13 | 日本パーカライジング株式会社 | 金属表面処理液、金属基材の表面処理方法及びそれにより得られた金属基材 |
WO2014124282A1 (en) | 2013-02-08 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Enhanced aav-mediated gene transfer for retinal therapies |
ES2704677T3 (es) | 2013-04-18 | 2019-03-19 | Fond Telethon | Suministro eficaz de genes grandes por vectores de AAV duales |
CA2912525A1 (en) | 2013-05-16 | 2014-11-20 | Applied Genetic Technologies Corporation | Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases |
GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
CA2942776C (en) | 2014-03-17 | 2023-01-24 | Adverum Biotechnologies, Inc. | Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter |
AU2015247777B2 (en) * | 2014-04-15 | 2019-03-21 | Beacon Therapeutics Limited | Codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) |
US20160206704A1 (en) | 2015-01-16 | 2016-07-21 | Isis Innovation Limited | Method |
WO2017106202A2 (en) * | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
-
2016
- 2016-12-13 WO PCT/US2016/066402 patent/WO2017106202A2/en active Application Filing
- 2016-12-13 EP EP20183330.8A patent/EP3795180A1/en active Pending
- 2016-12-13 BR BR112018011838-9A patent/BR112018011838A2/pt active Search and Examination
- 2016-12-13 AU AU2016370487A patent/AU2016370487C1/en active Active
- 2016-12-13 CA CA3008264A patent/CA3008264A1/en active Pending
- 2016-12-13 KR KR1020187019811A patent/KR20180099719A/ko active Search and Examination
- 2016-12-13 ES ES16852859T patent/ES2826384T3/es active Active
- 2016-12-13 US US16/061,530 patent/US11090392B2/en active Active
- 2016-12-13 MX MX2018007230A patent/MX2018007230A/es unknown
- 2016-12-13 CN CN201680081801.2A patent/CN109069668B/zh active Active
- 2016-12-13 RU RU2018125468A patent/RU2762747C2/ru active
- 2016-12-13 EP EP16852859.4A patent/EP3389724B1/en active Active
- 2016-12-13 JP JP2018531202A patent/JP7057281B2/ja active Active
-
2018
- 2018-06-13 MX MX2022010959A patent/MX2022010959A/es unknown
-
2019
- 2019-01-17 HK HK19100870.4A patent/HK1258518A1/zh unknown
-
2021
- 2021-07-07 US US17/369,525 patent/US20210330816A1/en active Pending
-
2022
- 2022-04-07 JP JP2022063749A patent/JP2022088656A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112018011838A2 (pt) | 2018-12-04 |
US20200061209A1 (en) | 2020-02-27 |
JP2019502378A (ja) | 2019-01-31 |
EP3795180A1 (en) | 2021-03-24 |
RU2018125468A (ru) | 2020-01-16 |
AU2016370487A1 (en) | 2018-07-05 |
WO2017106202A3 (en) | 2017-08-31 |
US11090392B2 (en) | 2021-08-17 |
JP7057281B2 (ja) | 2022-04-19 |
MX2022010959A (es) | 2022-10-07 |
CN109069668A (zh) | 2018-12-21 |
US20210330816A1 (en) | 2021-10-28 |
CA3008264A1 (en) | 2017-06-22 |
RU2018125468A3 (es) | 2020-10-22 |
CN109069668B (zh) | 2023-04-18 |
AU2016370487C1 (en) | 2022-03-03 |
EP3389724B1 (en) | 2020-07-01 |
JP2022088656A (ja) | 2022-06-14 |
KR20180099719A (ko) | 2018-09-05 |
ES2826384T3 (es) | 2021-05-18 |
WO2017106202A2 (en) | 2017-06-22 |
AU2016370487B2 (en) | 2021-08-05 |
EP3389724A2 (en) | 2018-10-24 |
HK1258518A1 (zh) | 2019-11-15 |
RU2762747C2 (ru) | 2021-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010959A (es) | Terapia genica para trastornos oculares. | |
IL252917A0 (en) | Vectors and vectors for gene therapy for use in the treatment of Wilson's disease | |
AU2024202345A1 (en) | Nucleic acid carriers and therapeutic methods of use | |
MX2017007127A (es) | Composiciones que comprenden polipeptidos que tienen actividad xilanasa y polipeptidos que tienen actividad arabinofuranosidasa. | |
IL280652A (en) | Nucleic acid molecules and their use for non-viral gene therapy | |
SI3233129T1 (sl) | Konstrukti nukleinske kisline in vektorji genske terapije za uporabo pri zdravljenju Wilsonove bolezni in drugih stanj | |
IL278058A (en) | Oligonucleotide compounds of 5-cap-tetranucleotide or higher and their uses in RNA production, protein expression and medicine | |
PL3159409T3 (pl) | Antysensowne kwasy nukleinowe do zastosowania do leczenia dystrofii mięśniowej duchenne'a | |
WO2014179331A3 (en) | Devices, systems and methods for optogenetic modulation of action potentials in target cells | |
MX2016013832A (es) | Composiciones y metodos para tratar hemoglobinopatias. | |
PH12018500568A1 (en) | Antisense nucleic acid | |
CY1123793T1 (el) | Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια | |
GB2571603B (en) | Hair treatment agent with anti-dandruff action | |
GB201513098D0 (en) | Catalytically active protein aggregates and methods for producing the same | |
MX2018013875A (es) | Composiciones que comprenden polipeptidos que tienen actividad galactanasa y polipeptidos que tienen actividad beta-galactosidasa. | |
EP3720509A4 (en) | GLOBING THERAPY FOR THE TREATMENT OF HEMOGLOBINOPATHIES | |
PT3253781T (pt) | Proteína dkk2 modificada, ácido nucleico que codifica a mesma, método de preparação da mesma e uso da mesma | |
IL274363B1 (en) | Use of a specific anti-protein siRNA for the treatment of hemophilia | |
Keswani et al. | Diversity, population and habitat used by spiders in bananaagro-ecosystem | |
MX2018014434A (es) | Composiciones que comprenden polipeptidos que tienen actividad galactanasa y polipeptidos que tienen actividad beta-galactosidasa. | |
EP3372249C0 (en) | AAV/UPR-PLUS VIRUS, UPR-PLUS FUSION PROTEIN, GENETIC TREATMENT METHOD AND USE THEREOF IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS PARKINSON'S DISEASE AND HUNTINGTON'S DISEASE | |
GB201522416D0 (en) | Wilson's disease gene therapy | |
EP3677680A4 (en) | SMALL NUCLEIC ACID ANTISENS GUIDE AND CORRESPONDING USE | |
EP3660163A4 (en) | NUCLEIC ACID HOMOGENIZATION METHOD AND KIT AND USES THEREOF | |
MX2021007688A (es) | Metodos para formar poliplejos. |